EVOQ Therapeutics has received USD 2 Million grant from the National Institutes of Health (NIH) to advance novel therapies for celiac disease.

The NIH award represents a significant endorsement of EVOQ's ground-breaking approach to harnessing the power of the immune system to treat and prevent autoimmune diseases.

"We are thrilled to receive this NIH grant, which underscores the potential of our NanoDisc technology to transform the immunotherapy landscape. This grant will enable us to accelerate development of a potential breakthrough therapy for this challenging autoimmune disease affecting 2.4 million Americans,” said Dr Weston Daniel, Chief Development Officer, EVOQ Therapeutics.

The NanoDisc technology leverages a proprietary platform that reduces the body's aberrant immune response underlying autoimmunity, offering a novel and highly effective method of re-educating the immune system's T regulatory cells (Tregs) via subcutaneous administration. This approach is designed to address unmet medical needs across a range of diseases by precisely reducing specific immune responses underlying autoimmunity.

"EVOQ Therapeutics remains committed to pushing the boundaries of immunotherapy innovation, and this NIH grant marks another important step forward in the company's mission to deliver desperately needed treatments to patients worldwide. It is particularly exciting to be awarded a grant for a technology that helps to cure autoimmune disease by inducing regulatory T cells, which were the subject of this year's Nobel Prize for Physiology and Medicine," said Dr David Giljohann, CEO, EVOQ Therapeutics.

In addition to celiac disease, EVOQ is developing therapies to treat type-I diabetes, Rheumatoid Arthritis (RA), lupus and a host of other chronic autoimmune diseases. These programmes leverage EVOQ's NanoDisc platform to precisely target the immune dysregulation underlying each disease.